Discover
UNCY
Unicycive Therapeutics, Inc.
5.28
2 x 3.76
2 x 5.73
bid
ask
+
0.59
12.58%
2 @ 04:00 PM
5.29 +0.01 (0.19%)
| Ytd | -8.49% | |
| 1y | 13.79% |
4.45
day range
5.30
3.71
52 week range
8.74
| Open | 4.57 | Prev Close | 4.69 | Low | 4.45 | High | 5.30 | Mkt Cap | 144.64M |
| Vol | 6.02M | Avg Vol | 1.30M | EPS | -2.25 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 7.47 | 200-d Avg | 6.26 | 1yr Est | 5.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.13 | -0.05 | 0.08 | 61.54% |
| 2024-08-14 | 2024-06 | -0.23 | N/A | N/A | N/A |
| 2024-08-14 | 2024-06 | -0.23 | -0.15 | 0.08 | 34.78% |
| 2024-05-13 | 2024-03 | -0.18 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.18 | -0.27 | -0.09 | -50.00% |
| 2024-03-28 | 2023-12 | -0.18 | -0.16 | 0.02 | 11.11% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-22 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-06 | Benchmark | Upgrade | Speculative Buy | Speculative Buy |
| 2024-09-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-08 | AGGARWAL GAURAV | Director | 0.00 | Conversion of Exercise of derivative security |
| 2023-07-10 | GUPTA PRAMOD | Officer | 41.85K | Conversion of Exercise of derivative security |
| 2023-07-10 | GUPTA SHALABH K | Chief Executive Officer | 2.53M | Conversion of Exercise of derivative security |
| 2023-07-10 | JERMASEK DOUGLAS | Officer | 175.01K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Great Point Partners LLC | 8.56M | 5.67M | 8.25% |
| 2024-09-29 | Octagon Capital Advisors LP | 8.56M | 5.67M | 8.25% |
| 2024-09-29 | Logos Global Management LP | 5.08M | 3.37M | 4.89% |
| 2024-09-29 | Walleye Capital LLC | 5.00M | 3.31M | 4.82% |
| 2024-09-29 | Vivo Capital, LLC | 4.47M | 2.96M | 4.31% |
| 2024-09-29 | SilverArc Capital Management, LLC | 4.00M | 2.65M | 3.85% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 765.00K | 507.19K | 0.74% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 373.22K | 247.44K | 0.36% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 229.42K | 152.10K | 0.22% |
| 2024-10-30 | Fidelity Total Market Index Fund | 71.49K | 47.40K | 0.07% |
| 2024-10-30 | iShares Micro Cap ETF | 65.37K | 43.34K | 0.06% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 54.03K | 35.82K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2025-06-20 |